# Rare Disease Clinical Trials - Global Strategic Business Report 2026: Capitalize on the $19.5 Billion Market as IQVIA, ICON, Parexel, and Labcorp Disrupt Trial Economics by 2032

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/rare-disease-clinical-trials-global-strategic-business-report-2026-capitalize-on-the-19-5/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Boost trial ROI with AI-led recruitment, decentralized and adaptive designs, real-world evidence, regulatory incentives, and strategic partnerships.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6068409/rare-disease-clinical-trials-global-strategic?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r48bk3&amp;utm_campaign=2404489+-+Rare+Disease+Clinical+Trials+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+the+%2419.5+Billion+Market+as+IQVIA%2c+ICON%2c+Parexel%2c+and+Labcorp+Disrupt+Trial+Economics+by+2032&amp;utm_exec=clshmsai" rel="nofollow">"Rare Disease Clinical Trials - Global Strategic Business Report 2026"</a> has been added to **ResearchAndMarkets.com's** offering.

**Global Rare Disease Clinical Trials Market to Reach US$19.5 Billion by 2032**

The global rare disease clinical trials market was valued at US$12.6 billion in 2025 and is projected to reach US$19.5 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.5% during the forecast period. Market growth is being supported by regulatory incentives, advances in genomic medicine, rising investment in orphan drug development and broader adoption of decentralized and patient-centric clinical trial models.

**Rare Disease Drug Development Gains Strategic Importance**

Rare disease clinical trials are becoming increasingly important to global biopharmaceutical research as companies, regulators and healthcare organizations address substantial unmet treatment needs. More than 7,000 rare diseases have been identified worldwide, creating demand for targeted therapies across genetic disorders, rare cancers, neurological conditions, hematologic disorders and other complex indications.

Government grants, tax credits, market exclusivity provisions, reduced regulatory fees and accelerated review pathways are encouraging pharmaceutical and biotechnology companies to expand orphan drug pipelines. Programs administered by the U.S. Food and Drug Administration and the European Medicines Agency continue to influence investment decisions, while adaptive trial designs and patient-focused protocols are improving the feasibility of studies involving small and geographically dispersed populations.

**Technology Transforms Rare Disease Clinical Trials**

Artificial intelligence and machine learning are strengthening patient identification and recruitment through the analysis of genomic profiles, electronic health records and clinical datasets. Real-world data and real-world evidence are also helping researchers evaluate disease progression, treatment response and long-term outcomes while supporting trial designs that may require smaller patient cohorts.

Virtual clinical trials, remote patient monitoring and decentralized research platforms are expanding access for participants who may otherwise face significant travel and logistical barriers. At the same time, biomarker-driven development, precision medicine, gene therapy, cell therapy and CRISPR-based research are accelerating the development of highly targeted treatment candidates. These technologies can improve protocol design, enhance data collection and increase the likelihood of clinically meaningful outcomes.

**Market Trends and Growth Drivers**

The rare disease clinical trials market is benefiting from increased patient advocacy, stronger collaboration among sponsors and research institutions, and growing use of global disease registries. Patient advocacy organizations are contributing to protocol development, recruitment strategies and retention initiatives, helping sponsors align studies more closely with participant needs.

Strategic partnerships among pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions and nonprofit organizations are also supporting innovation. Continued investment in personalized medicine, AI-enabled analytics and remote trial infrastructure is expected to reduce operational inefficiencies and accelerate regulatory submissions. These factors are positioning rare disease research as a significant area of long-term biopharmaceutical growth.

**Market Segment and Regional Outlook**

The report analyzes the rare disease clinical trials market by clinical phase, therapeutic area, sponsor type and geography. Clinical phase coverage includes Phase I, Phase II, Phase III and Phase IV trials. Therapeutic areas include oncology, cardiovascular disorders, neurological disorders, infectious diseases, genetic disorders, autoimmune and inflammatory conditions, hematologic disorders, musculoskeletal disorders and other indications. Sponsor categories include pharmaceutical and biotechnology companies, nonprofit organizations and other sponsors.

The Phase I segment is forecast to reach US$8.7 billion by 2032, advancing at a CAGR of 8.1%. The Phase II segment is projected to grow at a CAGR of 4.9% over the analysis period. Regionally, the U.S. rare disease clinical trials market was valued at US$3.7 billion in 2025. China is forecast to expand at a CAGR of 6.1% and reach US$3.4 billion by 2032. The report also evaluates market developments across Canada, Japan, Germany, the wider European market, Asia-Pacific and the Rest of World.

**Report Scope and Business Value**

-   Independent analysis of annual market value and forecasts from 2025 through 2032.
-   Assessment of major clinical phases, therapeutic areas, sponsor categories and geographic markets.
-   Evaluation of regulatory, technological and commercial factors influencing market expansion.
-   Competitive intelligence covering established pharmaceutical companies, biotechnology innovators and clinical research service providers.
-   Actionable insights to support portfolio planning, market entry, investment decisions and partnership strategies.
-   One year of complimentary updates covering relevant market developments.

**Domain Expert Insights and Differentiation**

The report incorporates perspectives from experts across industry, enterprise and academia to provide strategic context beyond conventional secondary research. The report tracks early market signals emerging from expert discussions, company activity, clinical development programs and market-relevant events before those developments are fully reflected in established research sources.

Its intelligence base includes conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications and other validated sources. These inputs are synthesized to identify market direction, competitive priorities and developments likely to influence future rare disease clinical trial strategies.

The analysis also extends beyond global market estimates to examine companies shaping the competitive environment. Where analytically relevant, market share is assessed at the regional level to reflect differences in regulatory frameworks, trial infrastructure, sponsor activity and therapeutic specialization.

**Companies Featured**

Companies covered in the rare disease clinical trials market report include Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Amgen Inc., Arcturus Therapeutics, AstraZeneca, Biogen Inc., Charles River Laboratories, Editas Medicine, F. Hoffmann-La Roche Ltd., Fortrea, ICON plc, IQVIA Inc., Labcorp Drug Development, Medpace, Novartis AG, Parexel International Corporation, Pfizer Inc., Precision for Medicine, PTC Therapeutics, Sanofi, Scholar Rock, Takeda Pharmaceutical Company, Ultragenyx Pharmaceutical Inc., United Therapeutics and Vertex Pharmaceuticals.

**Key Questions Addressed**

-   How will the global rare disease clinical trials market evolve through 2032?
-   Which regulatory, clinical and technological factors will drive or restrain growth?
-   Which clinical phases and therapeutic areas offer the strongest expansion opportunities?
-   How will regional market dynamics and competitive positions change during the forecast period?
-   Which companies are influencing rare disease drug development and clinical trial innovation?

As investment in orphan drugs, genomic medicine and decentralized research continues to increase, the global rare disease clinical trials market is expected to remain a critical component of biopharmaceutical innovation. Advanced trial designs, digital technologies and cross-sector collaboration will support the development of targeted therapies and improve prospects for patients with rare and complex diseases worldwide.

**Key Attributes:**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 183 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value (USD) in 2025 | $12.6 Billion |
| Forecasted Market Value (USD) by 2032 | $19.5 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |

  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6068409/rare-disease-clinical-trials-global-strategic?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r48bk3&amp;utm_campaign=2404489+-+Rare+Disease+Clinical+Trials+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+the+%2419.5+Billion+Market+as+IQVIA%2c+ICON%2c+Parexel%2c+and+Labcorp+Disrupt+Trial+Economics+by+2032&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/f7u0qz</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/YzMyYzQ5MjktNzgyMS00MGM3LTkyZDEtODRiYTY1NmY4NTFkLTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Metabolomics Market Size, Share, Growth, and Trends Analysis - Global Forecast to 2036 | Market to Reach USD 8.74 Billion as Clinical Diagnostics and AI Drive 9.5% CAGR](https://healthcarenews.io/news/metabolomics-market-size-share-growth-and-trends-analysis-global-forecast-to-2036-market-t.md)
- [Clinical Trial Management Systems (CTMS) - Global Strategic Business Report 2026: Capitalize on 17.5% CAGR to $7 Billion by 2032; Benchmark Oracle, Veeva Systems, Medidata Solutions and ArisGlobal](https://healthcarenews.io/news/clinical-trial-management-systems-ctms-global-strategic-business-report-2026-capitalize-on.md)
- [Clinical Trial Imaging - Global Strategic Business Report 2026: Capitalize on the $1.3 Billion Market as Bioclinica, Icon PLC, Parexel, and Ixico Disrupt AI-Driven Trials by 2032](https://healthcarenews.io/news/clinical-trial-imaging-global-strategic-business-report-2026-capitalize-on-the-1-3-billion.md)
- [E-Clinical Trial Technologies - Global Strategic Business Report 2026: Capitalize on 16.6% CAGR to US$32.8 Billion by 2032 as Oracle, Medidata, BioClinica and PAREXEL Disrupt Digital Trials](https://healthcarenews.io/news/e-clinical-trial-technologies-global-strategic-business-report-2026-capitalize-on-16-6-cag.md)
